Search results for " liver disease"

showing 10 items of 559 documents

SARS-CoV-2 infection in patients with a normal or abnormal liver.

2020

Abstract Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), a novel coronavirus causing coronavirus disease 19 (COVID‐19), with an estimated 22 million people infected worldwide so far although involving primarily the respiratory tract, has a remarkable tropism for the liver and the biliary tract. Patients with SARS‐CoV‐2 infection and no antecedent liver disease may display evidence of cytolytic liver damage, proportional to the severity of COVID‐19 but rarely of clinical significance. The mechanism of hepatocellular injury is unclear and possibly multifactorial. The clinical impact of SARS‐CoV‐2 infection in patients with underlying chronic liver disease, a cohort whose global …

Liver CirrhosisRiskmedicine.medical_specialtyCirrhosisCOVID-19 VaccinesCOVID-19 VaccineLiver CirrhosiPopulationDiseaseChronic liver diseasemedicine.disease_causeSARS‐CoV‐2Liver diseaseCOVID‐19VirologyInternal medicinevaccinemedicineHumansClinical significanceeducationCoronaviruseducation.field_of_studySettore MED/12 - GastroenterologiaHepatologybusiness.industryTransmission (medicine)SARS-CoV-2Liver DiseasescirrhosisCOVID-19chronic liver diseaseprioritizationmedicine.diseaseInfectious DiseasesLiverNon‐commissioned ReviewChronic DiseasebusinesscirrhosiHumanJournal of viral hepatitis
researchProduct

Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells

2020

ObjectiveLiver fibrosis constitutes a major health problem worldwide due to its rapidly increasing prevalence and the lack of specific and effective treatments. Growing evidence suggests that signalling through cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathways regulates liver fibrosis and regeneration. Rilpivirine (RPV) is a widely used anti-HIV drug not reported to produce hepatotoxicity. We aimed to describe the potential hepatoprotective effects of RPV in different models of chronic liver injury, focusing on JAK-STAT signalling regulation.DesignThe effects of RPV on hepatic steatosis, inflammation and fibrogenesis were studied in a nut…

Liver CirrhosisSTAT3 Transcription Factor0301 basic medicineApoptosisRisk AssessmentSensitivity and SpecificityMice03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisHepatic Stellate CellsmedicineAnimalsHumansSTAT1610 Medicine & healthSTAT3Cells CulturedLiver injurybiologybusiness.industryRilpivirineFatty liverGastroenterologymedicine.diseaseLiver regenerationLiver RegenerationDisease Models AnimalSTAT1 Transcription FactorTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisbiology.proteinHepatic stellate cellCancer researchbusinessJanus kinase
researchProduct

Color Doppler Ultrasound in Portal Hypertension

2020

Portal hypertension is one of the most important causes of morbidity and mortality in cirrhotic patients. A color Doppler evaluation of the left gastric vein (LGV) has proven utility in the prediction of esophageal varices and variceal bleeding in patients with portal hypertension. The purpose of this review is to discuss the ultrasound evaluation, imaging findings, and clinical application of Doppler ultrasound in the assessment of the LGV. Knowledge of the color Doppler technique and imaging findings of the LGV may help clinicians improve the monitoring of portal hypertension and predict patients with a high risk of esophageal varices.

Liver Cirrhosisesophageal varicemedicine.medical_specialtyleft gastric veinLeft gastric veinHemodynamicsEsophageal and Gastric Varicesurologic and male genital diseasesChronic liver disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalHumansMedicineRadiology Nuclear Medicine and imagingUltrasonography Doppler Color030219 obstetrics & reproductive medicineRadiological and Ultrasound TechnologyPortal Veinultrasoundbusiness.industryUltrasoundHemodynamicschronic liver diseaseportal hypertensionColor doppler ultrasoundColor dopplermedicine.diseasefemale genital diseases and pregnancy complicationsPortal hypertensionRadiologycolor DopplerGastrointestinal HemorrhagebusinessJournal of Ultrasound in Medicine
researchProduct

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice.

2020

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main …

Liver Cirrhosismedicine.medical_specialtyBest practicePsychological interventionMEDLINEDiseasedigestive systemRisk Assessment03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasemedicineHumansMass ScreeningIntensive care medicinebusiness.industryPublic healthGastroenterologymedicine.diseaseAdvanced fibrosis Best practice Identification NAFLD NASHdigestive system diseasesEarly Diagnosis030220 oncology & carcinogenesisPractice Guidelines as TopicDisease Progression030211 gastroenterology & hepatologyIdentification (biology)businessAlgorithmsJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta -Analysis

2020

Background & Aims:\ud Biopsy-confirmed liver fibrosis is a prognostic factor for patients with nonalcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the prognostic value of fibrosis stage in patients with NAFLD and the subgroup of patients with nonalcoholic steatohepatitis (NASH) and to assess the evidence that change in fibrosis stage is a surrogate endpoint.\ud \ud Methods:\ud We searched the MEDLINE, Embase, Cochrane Library, and trial registry databases through August 2018 for prospective or retrospective cohort studies of liver-related clinical events and outcomes in adults with NAFLD or NASH. We collected data on mortality (all cause and liver rela…

Liver Cirrhosismedicine.medical_specialtyBiopsyRisk AssessmentSeverity of Illness IndexLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineRisk of mortalityHumansHepatologybusiness.industrySurrogate endpointGastroenterologyKlinisk medicinRetrospective cohort studyConfounding Factors Epidemiologicmedicine.diseasePrognosisdigestive system diseasesLiverRelative riskMeta-analysisQuality of LifeClinical Medicinebusiness
researchProduct

Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma

2012

Interleukin-6 (IL-6) is a pleiotropic cytokine which is expressed in many inflammatory cells in response to different types of stimuli, regulating a number of biological processes. The IL-6 gene is polymorphic in both the 5’ and 3’ flanking regions and more than 150 single nucleotide polymorphisms have been identified so far. Genetic polymorphisms of IL-6 may affect the outcomes of several diseases, where the presence of high levels of circulating IL-6 have been correlated to the stage and/or the progression of the disease itself. The -174 G/C polymorphism is a frequent polymorphism, that is located in the upstream regulatory region of the IL-6 gene and affects IL-6 production. However, the…

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusSingle-nucleotide polymorphismBiologyChronic liver diseasemedicine.disease_causePolymorphism Single NucleotideGastroenterologyHepatitis B ChronicNon-alcoholic Fatty Liver DiseaseRisk FactorsChronic hepatitis Hepatocellular carcinoma Interleukin-6 Liver cirrhosis Single nucleotide polymorphismsInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseTopic HighlightLiver Diseases AlcoholicInterleukin-6Liver NeoplasmsFatty liverGastroenterologyGeneral MedicineHepatitis C ChronicHepatitis Bmedicine.diseaseFatty LiverHepatitis AutoimmunePhenotypeHepatocellular carcinomaImmunologySteatohepatitisWorld Journal of Gastroenterology
researchProduct

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensate…

2021

[Background & Aims] Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaNASH; cACLD; prognostic factor; steatohepatitis[SDV]Life Sciences [q-bio]cACLD; NASH; Prognostic Factor; Steatohepatitis; Gastrointestinal Hemorrhage; Humans; Liver; Liver Cirrhosis; Retrospective Studies; Carcinoma Hepatocellular; Elasticity Imaging Techniques; Esophageal and Gastric Varices; Liver Neoplasms; Non-alcoholic Fatty Liver Disease610 Medicine & healthEsophageal and Gastric VaricesChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInterquartile rangeInternal medicineAscitesNonalcoholic fatty liver diseasemedicineHumansComputingMilieux_MISCELLANEOUSRetrospective StudiesSteatohepatitisHepatologybusiness.industryPrognostic FactorsteatohepatitiCarcinomaLiver NeoplasmsHazard ratioGastroenterologyNASHHepatocellularcACLDmedicine.disease3. Good healthLiver030220 oncology & carcinogenesisHepatocellular carcinomaElasticity Imaging Techniques030211 gastroenterology & hepatologySteatohepatitismedicine.symptomGastrointestinal HemorrhageTransient elastographybusiness
researchProduct

Congenital Cystic Lesions of the Bile Ducts: Imaging-Based Diagnosis

2020

Congenital cystic lesions of the bile ducts represent a spectrum of liver and biliary system lesions, resulting from abnormal embryologic development of the ductal plate. These disorders include Caroli disease, choledochal cysts, autosomal dominant polycystic liver disease, congenital hepatic fibrosis, and biliary hamartomas. Each disorder carries a peculiar clinical presentation, prognosis, and risk of complications. Knowledge of radiological findings of fibropolycystic liver diseases is crucial for their appropriate detection and for differential diagnosis with other similar hepatic cystic lesions, in order to avoid relevant misdiagnosis. The aim of this review is to provide an illustrati…

Liver Cirrhosismedicine.medical_specialtyCaroli diseaseDigestive System DiseasesHamartomaCystic lesions030218 nuclear medicine & medical imagingDiagnosis Differential03 medical and health sciencesCystic lesion0302 clinical medicineMedicineHumansRadiology Nuclear Medicine and imagingCholedochal cystsFibropolycystic liver diseasemedicine.diagnostic_testbusiness.industryCystsPolycystic liver diseaseLiver DiseasesUltrasoundGenetic Diseases InbornMagnetic resonance imagingmedicine.diseaseCaroli DiseaseLiver030220 oncology & carcinogenesisCongenital hepatic fibrosisRadiologyDifferential diagnosisbusinessSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

The association between education level and chronic liver disease of any etiology

2020

Abstract Background The potential link between educational level and chronic liver diseases (CLD) were explored using the mortality records of liver cirrhosis, which lack accuracy and are unable to identify the different etiological factors of liver cirrhosis. Information on the association of low educational level with the severity of CLD is lacking. Aim To evaluate the potential association linking education level to etiology and clinical stage of CLD cases. Methods Consecutive enrolment of 11,107 subjects with CLD aged≥18 years prospectively recruited in two national surveys in 2001 and 2014 at one of the participating Italian liver units throughout the country. Subjects were pooled in t…

Liver Cirrhosismedicine.medical_specialtyCirrhosisAlcohol DrinkingLiver CirrhosiDisease030204 cardiovascular system & hematologyEducational settingChronic liver diseaseLogistic regressionChronic disease03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineHBVInternal MedicinemedicineHumans030212 general & internal medicineStage (cooking)Association (psychology)Non-alcoholic Fatty Liver Disease.business.industryLiver DiseasesLiver DiseaseFatty liverMiddle Agedmedicine.diseaseItalyHCVEtiologyLiver disorderAlcoholbusinessHumanLiver disordersEuropean Journal of Internal Medicine
researchProduct

The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.

2020

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, involving about 25% of people. NAFLD incorporates a large spectrum of pathological conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and its complications include hepatic decompensation and hepatocellular carcinoma (HCC). This progression occurs, over many years, in an asymptomatic way, until advanced fibrosis appears. Thus, the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis are key issues. To date, the histological assessment of fibrosis with liver biopsy is the gold standard, but obviously, invasiveness is the …

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularBiopsyDiseaseGastroenterology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineDrug DiscoverymedicineHumansPharmacologymedicine.diagnostic_testbusiness.industryFatty liverLiver Neoplasmsnutritional and metabolic diseasesBiomarkers FibroScan Fibrosis MRE MRI NAFLD NASH Non-invasive testsmedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinoma030211 gastroenterology & hepatologySteatohepatitisbusinessHepatic fibrosisCurrent pharmaceutical design
researchProduct